CRNX - Crinetics Pharmaceuticals, Inc.
About Crinetics Pharmaceuticals, Inc. (https://www.crinetics.com)
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| R. Scott Struthers | Founder, President, Chief Executive Officer & Director | 1962 | $1,187,855 USD |
| Tobin C. Schilke | Chief Financial Officer | 1975 | $1,022,423 USD |
| Stephen F. Betz | Co-Founder & Chief Scientific Officer | 1966 | $755,150 USD |
| Alan S. Krasner | Chief Endocrinologist | 1963 | $653,924 USD |
| Adriana Cabre | Chief Human Resources Officer | – | – |
| Chris Robillard | Chief Business Officer | – | – |
| Garlan Adams | Chief Legal Officer & Corporate Secretary | – | – |
| Gayathri Diwakar | Senior Director of Investor Relations | – | – |
| Kea Lingo | Chief Information Officer | – | – |
| Kevin Capps | Head of Intellectual Property | – | – |